Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline

Open access
Husebye, Eystein S, Castinetti, Frederik, Criseno, Sherwin, Curigliano, Giuseppe, Decallonne, Brigitte, Fleseriu, Maria, Higham, Claire E, Lupi, Isabella, Paschou, Stavroula A, Toth, Miklos, van der Kooij, Monique, Dekkers, Olaf M · 2022 · European Journal of Endocrinology

Abstract

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but are associated with significant autoimmune endocrinopathies that pose both diagnostic and treatment challenges. The aim of this guideline is to provide clinicians with the best possible evidence-based recommendations for treatment and follow-up of patients with ICI-induced endocrine side-effects based on the Grading of Recommendations Assessment, Development, and Evaluation system. As these drugs have been used for a relatively short time, large systematic investigations are scarce. A systematic approach to diagnosis, treatment, and follow-up is needed, including baseline tests of endocrine function before each treatment cycle. We conclude that there is no clear evidence for the benefit of high-dose glucocorticoids to treat endocrine toxicities with the possible exceptions of severe thyroid eye disease and hypophysitis affecting the visual apparatus. With the exception of thyroiditis, most endocrine dysfunctions appear to be permanent regardless of ICI discontinuation. Thus, the development of endocrinopathies does not dictate a need to stop ICI treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-22-0689

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 192

Metadata

Authors
Husebye, E. S., Castinetti, F., Criseno, S., Curigliano, G., Decallonne, B., Fleseriu, M., Higham, C. E., Lupi, I., Paschou, S. A., Toth, M., van der Kooij, M., & Dekkers, O. M.
Venue
European Journal of Endocrinology
Published
2022-10-25
Volume
187
Issue
6
Pages
G1-G21
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W4296798904
Cited by
192
References
41
FWCI
11.42
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. https://app.cochat.ai/papers/10.1530/eje-22-0689
The paper
Husebye, E. S., Castinetti, F., Criseno, S., Curigliano, G., Decallonne, B., Fleseriu, M., Higham, C. E., Lupi, I., Paschou, S. A., Toth, M., van der Kooij, M., & Dekkers, O. M. (2022). Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. European Journal of Endocrinology. https://doi.org/10.1530/eje-22-0689

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.